Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALA: neratinib + capecitabine versus lapatinib + capecitabine in HER2-positive metastatic breast cancer
NL-OMON47471Phase 3Active, not recruiting
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Dec 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Neratinib + capecitabine with Lapatinib + capecitabine (2 arms). Primary endpoints: Independently assessed progression-free survival and Overall survival. Started Dec 2016; status: active, not recruiting.
02
Drugs
neratiniblapatinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47471.